Neoplasms

Nervous System Diseases

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Prolactinoma

Adenoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Pituitary Diseases

Pituitary Neoplasms

Endocrine Gland Neoplasms

Hypothalamic Diseases

Brain Diseases

Central Nervous System Diseases

Endocrine System Diseases

All Drugs and Chemicals

Cardiotonic Agents

Hormones

Dopamine

Dopamine Agonists

Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume,visual acuity and visual field scale will be measured every 3 months.MRI showed that the tumors shrunk significantly.

Subjects are treated with CAB tablets 2mg/week or BC tablets 7.5mg/day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The CAB or BC fail to decrease prolactinoma size.

The medication will be stopped if failure to decrease prolactinoma size and the subjects will be advised to endoscopic transphenoidal pituitary surgery .

Surgery

The medication will continue if DA causes tumors to shrink.

Drug treatment

Weiting Gu, MD

Zhebao Wu, Medical PhD

To study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.

The dopamine agonist(DA),such as cabergoline(CAB) and bromocriptine(BC), has been used widely in the treatment of prolactinomas, but its clinical use is hampered by intolerance and/or resistant in some patients. It had been showed that DA inhibit prolactin secretion by binding to and activating dopamine D2 receptors.PET-MR combined MR images with PET function images is substantial to evaluate the expression of dopamine D2 receptors.The aim is to study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of DA.

Dopamine D2 Receptors(D2R) Imaging in Prolactinomas

The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of of Prolactinomas.

The individual patient Data would not be shared to the third facility, but the sponsor hasn't decided whether to share the individual patient date to the other related studies hold by himself in the future.

Record the result of PRL on every 3 month follow-up visit

Record the tumor volume from enhanced pituitary MRI on every 3 month follow-up visits

Record the Visual field scale on every 3 month follow-up visit, 0 = normal, no vision loss; 1 = one quadrant vision loss; 2 = two quadrants of vision loss; 3 = three quadrants of vision loss; 4 = four quadrants of vision loss but retain a central tubular vision; 5 = blind

Record the Visual acuity on every 3 month follow-up visit.

Xinqiao Hospital of Chongqing

First Hospital of China Medical University

Beijing Tiantan Hospital

First Affiliated Hospital of Wenzhou Medical University

First Affiliated Hospital of Fujian Medical University

Peking Union Medical College Hospital

Huashan Hospital

Chinese PLA General Hospital

Zhebao Wu

Principal Investigator

Hypothalamic Neoplasms

Supratentorial Neoplasms

Brain Neoplasms

Central Nervous System Neoplasms

Nervous System Neoplasms

Anti-Dyskinesia Agents

Cabergoline

Bromocriptine

Subjects who show high expression of dopamine D2 receptors in PET-MR imaging.

Subjects who show low expression of dopamine D2 receptors in PET-MR imaging.

Subjects who show high expression of dopamine D2 receptors in PET-MR imaging will be treated with Cabergoline(CAB) tablets 2mg/week or bromocriptine(BC) tablets 7.5mg/ day.The pituitary hormone levels, tumor volume, visual acuity and visual field scale will be measured every 3 months. The medication will be stopped if failure to decrease tumor size and the subjects will be advised to surgical therapy.

Subjects who show low expression of dopamine D2 receptors in PET-MR imaging will be treated with endoscopic transphenoidal pituitary surgery .

To study the in vivo expression of dopamine D2 receptors in nonfunctioning pituitary adenoma and the predictive role of dopamine dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists（DA）.

Dopamine agonists are the first line therapy for prolactinoma,which are also effective in some cases of other subtypes of pituitary tumors. It had been showed that dopamine agonists inhibit prolactin secretion by binding to and activating dopamine D2 receptors. PET-MR combined MR images with PET function images is substantial to evaluate the expression of dopamine D2 receptors.The aim is to study the in vivo expression of dopamine D2 receptors in prolactinoma and the predictive role of dopamine D2 receptors PET-MR imaging in the therapeutic effect of dopamine agonists.

Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)

The Predictive Value of Positron Emission Tomography-Magnetic Resonance (PET-MR) Mediated Dopamine D2 Receptors Imaging in the Drug Therapy of Nonfunctioning Pituitary Adenoma

Change from baseline on tumor volume measured by enhanced pituitary Magnetic Resonance Imaging（MRI）.

Record the tumor volume from enhanced pituitary MRI on every 3 month follow-up visit.

2.Record the Visual field scale on every 3 month follow-up visit, 0 = normal, no vision loss; 1 = one quadrant vision loss; 2 = two quadrants of vision loss; 3 = three quadrants of vision loss; 4 = four quadrants of vision loss but retain a central tubular vision; 5 = blind

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas	NCT03717454	Prolactinoma	Surgery Drug treatment	18 Years - 65 Years	Ruijin Hospital
Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)	NCT03714763	Pituitary Adeno...	Drug treatment Surgery	18 Years - 65 Years	Ruijin Hospital
Dopamine D2 Receptors(D2R) Imaging in Prolactinomas	NCT03717454	Prolactinoma	Surgery Drug treatment	18 Years - 65 Years	Ruijin Hospital

Spots Global Cancer Trial Database for dopamine d2 receptors